Document ID: chunk:federal_register_of_legislation:F2025L00155:front:0:p2
Version: federal_register_of_legislation:F2025L00155
Segment Type: other
Provision Reference: 
Character Range: 3066–6046

injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.
Death from malignant neoplasm of the endometrium
 1.           For the purposes of this Statement of Principles, malignant neoplasm of the endometrium, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's malignant neoplasm of the endometrium.
Note: terminal event is defined in the Schedule 1 – Dictionary.
 1.                Basis for determining the factors
On the sound medical‑scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that malignant neoplasm of the endometrium and death from malignant neoplasm of the endometrium can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.
Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.
 1.                Factors that must exist
At least one of the following factors must exist before it can be said that, on the balance of probabilities, malignant neoplasm of the endometrium or death from malignant neoplasm of the endometrium is connected with the circumstances of a person's relevant service:
 1.           for females aged over 35 years only, having never been pregnant for more than 8 weeks, at the time of clinical onset;
 2.           using oestrogen-only hormone replacement therapy for at least 6 months before clinical onset, and where the use of oestrogen-only hormone replacement therapy has ceased, clinical onset has occurred within 20 years of cessation;
Note: oestrogen-only hormone replacement therapy is defined in the Schedule 1 - Dictionary.
 1.           having cyclical combined hormone replacement therapy where oestrogen is combined with cyclical administration of progesterone for less than 15 days during each treatment cycle, for a continuous period of at least 5 years before clinical onset. Where the use of cyclical combined hormone replacement therapy has ceased, clinical onset has occurred within 5 years of cessation;
 2.           for post-menopausal females only, undergoing treatment with tamoxifen for at least 3 months before clinical onset, and where treatment has ceased, clinical onset has occurred within 20 years of cessation.
 3.           being overweight or obese for a period of at least 10 years within the 20 years before clinical onset;
Note: being overweight or obese is defined in the Schedule 1 - Dictionary.
 1.           having diabetes mellitus for at least 10 years before clinical onset;
 2.           an inability to undertake any physical activity greater than 3 METs for at least 10 years within the 30 years before clinical onset;
Note: MET is defined in